Medtech counterfeiting on LatAm agenda as Brazil prepares Mercosur presidency
This article was originally published in Clinica
Tackling medtech and pharma counterfeit products is a leading healthcare-related priority for Latin America’s Mercosur group of nations, the Brazilian health ministry has said as it prepares to take over the bloc’s rotating six-month presidency.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.